BACKGROUND:Artemisinin-based combination therapies (ACTs) are highly efficacious and safe, but data from human immunodeficiency virus (HIV)-infected children concurrently receiving antiretroviral therapy (ART) and ACTs are limited. METHODS: We evaluated 28-day outcomes following malaria treatment with artemether-lumefantrine (AL) or dihydroartemisinin-piperaquine (DP) in 2 cohorts of HIV-infected Ugandan children taking various ART regimens. In one cohort, children <6 years of age were randomized to lopinavir/ritonavir (LPV/r) or nonnucleoside reverse transcriptase inhibitor-based ART and treated with AL for uncomplicated malaria. In another cohort, children <12 months of age were started on nevirapine-based ART if they were eligible, and randomized to AL or DP for the treatment of their first and all subsequent uncomplicated malaria episodes. RESULTS: There were 773 and 165 treatments for malaria with AL and DP, respectively. Initial response to therapy was excellent, with 99% clearance of parasites and <1% risk of repeat therapy within 3 days. Recurrent parasitemia within 28 days was common following AL treatment. The risk of recurrent parasitemia was significantly lower among children taking LPV/r-based ART compared with children taking nevirapine-based ART following AL treatment (15.3% vs 35.5%, P = .009), and those treated with DP compared with AL (8.6% vs 36.2%, P < .001). Both ACT regimens were safe and well tolerated. CONCLUSIONS: Treatment of uncomplicated malaria with AL or DP was efficacious and safe in HIV-infected children taking ART. However, there was a high risk of recurrent parasitemia following AL treatment, which was significantly lower in children taking LPV/r-based ART compared with nevirapine-based ART.
RCT Entities:
BACKGROUND:Artemisinin-based combination therapies (ACTs) are highly efficacious and safe, but data from human immunodeficiency virus (HIV)-infectedchildren concurrently receiving antiretroviral therapy (ART) and ACTs are limited. METHODS: We evaluated 28-day outcomes following malaria treatment with artemether-lumefantrine (AL) or dihydroartemisinin-piperaquine (DP) in 2 cohorts of HIV-infected Ugandan children taking various ART regimens. In one cohort, children <6 years of age were randomized to lopinavir/ritonavir (LPV/r) or nonnucleoside reverse transcriptase inhibitor-based ART and treated with AL for uncomplicated malaria. In another cohort, children <12 months of age were started on nevirapine-based ART if they were eligible, and randomized to AL or DP for the treatment of their first and all subsequent uncomplicated malaria episodes. RESULTS: There were 773 and 165 treatments for malaria with AL and DP, respectively. Initial response to therapy was excellent, with 99% clearance of parasites and <1% risk of repeat therapy within 3 days. Recurrent parasitemia within 28 days was common following AL treatment. The risk of recurrent parasitemia was significantly lower among children taking LPV/r-based ART compared with children taking nevirapine-based ART following AL treatment (15.3% vs 35.5%, P = .009), and those treated with DP compared with AL (8.6% vs 36.2%, P < .001). Both ACT regimens were safe and well tolerated. CONCLUSIONS: Treatment of uncomplicated malaria with AL or DP was efficacious and safe in HIV-infectedchildren taking ART. However, there was a high risk of recurrent parasitemia following AL treatment, which was significantly lower in children taking LPV/r-based ART compared with nevirapine-based ART.
Authors: Moses R Kamya; Anne F Gasasira; Adoke Yeka; Nathan Bakyaita; Samuel L Nsobya; Damon Francis; Philip J Rosenthal; Grant Dorsey; Diane Havlir Journal: J Infect Dis Date: 2005-11-18 Impact factor: 5.226
Authors: Paul Edward Okello; Wim Van Bortel; Anatol Maranda Byaruhanga; Anne Correwyn; Patricia Roelants; Ambrose Talisuna; Umberto D'Alessandro; Marc Coosemans Journal: Am J Trop Med Hyg Date: 2006-08 Impact factor: 2.345
Authors: Qing Ma; Olanrewaju O Okusanya; Patrick F Smith; Robert Dicenzo; Judianne C Slish; Linda M Catanzaro; Alan Forrest; Gene D Morse Journal: Expert Opin Drug Metab Toxicol Date: 2005-10 Impact factor: 4.481
Authors: Zara Shubber; Alexandra Calmy; Isabelle Andrieux-Meyer; Marco Vitoria; Françoise Renaud-Théry; Nathan Shaffer; Sally Hargreaves; Edward J Mills; Nathan Ford Journal: AIDS Date: 2013-06-01 Impact factor: 4.177
Authors: Shufeng Zhou; Sui Yung Chan; Boon Cher Goh; Eli Chan; Wei Duan; Min Huang; Howard L McLeod Journal: Clin Pharmacokinet Date: 2005 Impact factor: 5.577
Authors: Kay Seden; Sara Gibbons; Catia Marzolini; Jonathan M Schapiro; David M Burger; David J Back; Saye H Khoo Journal: PLoS One Date: 2017-03-23 Impact factor: 3.240
Authors: Jose Francis; Karen I Barnes; Lesley Workman; Tamara Kredo; Lasse S Vestergaard; Richard M Hoglund; Pauline Byakika-Kibwika; Mohammed Lamorde; Stephen I Walimbwa; Ifeyinwa Chijioke-Nwauche; Colin J Sutherland; Concepta Merry; Kimberley K Scarsi; Nyagonde Nyagonde; Martha M Lemnge; Saye H Khoo; Ib C Bygbjerg; Sunil Parikh; Francesca T Aweeka; Joel Tarning; Paolo Denti Journal: Antimicrob Agents Chemother Date: 2020-04-21 Impact factor: 5.191
Authors: T Kredo; K Mauff; L Workman; J S Van der Walt; L Wiesner; P J Smith; G Maartens; K Cohen; K I Barnes Journal: BMC Infect Dis Date: 2016-01-27 Impact factor: 3.090